A day AGI rjs shares Joe’s post on filing of IND. Joe

New Post Public Reply Private Reply Replies (0) Message Board
tc2000chartreader OrlandoJohn #18824
386
A day AGI rjs shares Joe’s post on filing of IND.

Joe comment

In my opinion long term sustained memory like our 10 year breast cancer vaccine data that was just released is the only way, and none of the other pathways like mRNA have that or significant positive with big benefit data, unless I missed it, so, a lotta work ahead!

Digi comment

There is no long term sustained protection from the coronavirus. Crap, make a cold vaccine and maybe we could believe you. Reality is Joe, it can't be done due to the mutations that take place in a short amount of time. You really want liability or did you get Nu Generex into the "Not being able to be prosecuted thing". Reality Joe.

Joe comment

Chuck Merchant that is a ridiculous statement, get facts Chuck, a subunit pathway works with epitopes, epitopes change minutely from one strain to another, example, SARS Corona 2002 is a 80 percent match from SARS to COVID 19 so to enlighten you a vaccine made for SARS with subunit antibody (Humeral) and Cellular cd4 and 8 protection would work fine with protection today, its the ones doing full spike protein that have the problems with your ridiculous uninformed comment. Comments like this are not smart, irresponsible and for sure disgustingly stupid.

Rjs comment

Chuck Merchant hey bud, the long term memory Joe referred to was proven in the Phase II breast cancer vaccine study cs the Phase I prostate vaccine study. That’s remarkable and confirms optimism for the Ii-Key CD 4, CD 8 whole vaccine approach. Such a peptide vaccine can later be specially designed for future mutations. Testing for safety, immunological response and efficacy is key though for the NuGenerex Covid vaccine. Joe can correct any of that if I’m wrong.

Digi comment

Honest question Joe. Would you take the first vaccine that Nu Generex produces?


BTW Joe, you do know that the SARS vaccine that was given to the Chinese folks produced about a 90% fatality rate when this second wave came around. It's fact if you check it. Point is Joe, it seems like there is no vaccine that can be made to protect folks. If I am wrong, then please provide me with FACTS to show that I am wrong. Fair enough?

Joe comment

Chuck Merchant I would never take a rna, dna and especially a mRNA vaccine if it’s anything less then 100 percent which they will not be that I guarantee, and if not 100 percent he’ll no, because the off targets will kill me, and if I get it again with that vaccine the off targets will kill me like cytokine storm and any of the other 20-30 off target auto immune events that could occur, but first and foremost you would have to show me any data that these pathways have any data prior that is significant positive and gives benefit, but there is none because after all the failures they finally figured it out for Covid and that’s just bullshit.


And yes I would take the first vaccine Generex produces because we never had off targets and we are the only one unless I’m wrong and missed something that has significant positive benefit data from something else, again I could be wrong but if I am someone needs to prove it to me.

And to date no ones proved nothing. Period! End of story!

Chuck Merchant have no idea what vaccine or pathway your talking about, I do know your warp speed leader from GSK killed more people then anyone in England on his GSK vaccines and ooops I forgot all those pediatrics. And I’m sure if o viral vector or use of all spike protein, non dehumanized and live virus particles it killed more then you know.

You should really stay away from science Chuck and stick to computers, oops i forgot that great philanthropist Bill Gates who couldn’t solve his viruses in his own product at Microsoft and has made 100 times more then he pretended to give away will solve this problem, hahahahaha!

Digicomment

Covid has a 3-6 month memory in our systems. Already proven. Joe just wants the price to spike. And BTW, mRNA is a disaster. It can change systematic DNA to what the mRNA wants it to do. Do some checking on it RJ.

Joe comment

Chuck Merchant says who show me the data as the fda would say

Chuck Merchant antibodies disappear in 30-60 days after getting over Covid, and no one like Moderna wants to give their full data, and my belief it’s the same otherwise from their phase one the first thing I’d be trumpeting is 30, 60, 90 days still robust antibody with cd4, cd8 long term memory tcell activation, but no one is saying that, and please with Oxford they are notorious exaggerators, it’s a really good business buying or giving someone 2-300 million, spend another 500 million to know what you know already, failure but your big time Lobbiest sin Washington plus your buddies give you a 1.6 billion dollar contract and make even with failure 100’s of millions, now that’s a great business, none of the partnerships would have ever of happened with big pharma if Covid did not take place and all the free cash, and all those great Lobbiest sin Washington that work for big pharma cause they pay millions a quarter, it’s really funny to me all the contracts went to companies with zero product but they got contracts only after they bought someone else’s product, hahaha do your DD.

Chuck Merchant and stop with the ridiculous comments, talk to me when I’m right in 3 mos.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 3

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
Hims & Hers Faces Lawsuit as FTC Alleges Privacy Breach

Updated Category News Views 4

FTC Cracks Down on Hims & Hers Privacy Practices Most folks don't wake up wanting to find their investments tangled in legal drama. But here we are with Hims & Hers Health (NYSE: HIMS), facing fire from the Federal Trade Commission (FTC). They’re being called out for allegedly spilling the beans on users' sensitive health data—something they claimed to keep under...

Continue Reading
Sarepta Under Scrutiny: KSF's Investigation Deepens

Updated Category News Views 5

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Continue Reading
CHiQ Secures AI Award, Elevates Smart Home Living

Updated Category News Views 2

CHiQ's Big Win in the AI Game In a world where technology rarely stops spinning, CHiQ has carved its own commendable niche. Snagging the AI Home Ecosystem Brand Award at IFA 2026 in Berlin, the brand's knack for pioneering AI tech isn't just a footnote—it's the whole story. The award—enough to make your competitors green with envy—highlights how far they've come in...

Continue Reading
York Space Systems Faces Class Action Headwinds

Updated Category News Views 4

York Space Systems: Under Legal Fire You ever hear the one about York Space Systems? Yeah, their ticker YSS is buzzing for all the wrong reasons. Not even a year out from their IPO, and already they're tangled in a class action lawsuit that's got investors with their heads in their hands. ClaimsFiler, a shareholder information outfit, just blasted out a reminder for...

Continue Reading
ToolDance X1 CNC Mill Unveils at IFA 2026

Updated Category News Views 1

IFA 2026 Reveals a Game Changer: ToolDance X1 Listen up, because ToolDance just threw a curveball into the CNC world with the launch of their X1 Smart Desktop CNC Mill at the IFA 2026 in Berlin. This isn't just another gadget—it's a real player aiming to bring manufacturing muscle right to your desktop. Will Wang, the genius behind ToolDance, wants to democratize CNC...

Continue Reading
Consumer365 Lauds Happy Head's Custom Hair Treatments

Updated Category News Views 6

Revolutionizing Hair Loss Treatment The world of hair growth solutions is transforming right before our eyes. Thanks to the folks over at Happy Head and their customizable, dermatologist-prescribed treatments, the days of one-size-fits-all are ending. Consumer365 recently took a dive into Happy Head's model, giving their nod of approval to its personalized approach....

Continue Reading
Why Buyers Are Flocking to Whidbey Island Homes

Updated Category News Views 0

Something's got folks eyeing Whidbey Island like a gambler with a hot tip—and it ain't just the thrill of a vacation spot. Anyone with half a brain knows real estate moves in waves, and right now, Whidbey Island's caught some serious momentum. You can't ignore the pull of natural beauty, access to city life, and that laid-back vibe that seems to whisper "slow down and...

Continue Reading
Tuya Presents Doova: A Senior-Friendly AI Robot

Updated Category News Views 3

IFA Unveils a Game-Changer for Senior Living Imagine having a helper at home that not only looks out for your safety but also keeps you company. That's exactly what Tuya Smart's new AI creation, Doova, is set to do. Unveiled at the IFA 2026, Doova isn't just another gadget—it’s a big leap for folks choosing to live out their golden years independently. Navigating...

Continue Reading
LiberNovo Spotlights Ergonomic Seating at Berlin's IFA 2026

Updated Category News Views 0

LiberNovo Sets the Stage at IFA 2026 If you're poking around Berlin this September, the Messe Berlin is the place to be, especially for those keeping tabs on the consumer tech world. LiberNovo, the ergonomic seating company you might not have had on your radar, is out here making noise. They're throwing down the gauntlet with the Maxis Series, promising a better deal for...

Continue Reading

Top 5 Most Recently Viewed Articles

Celsius Holdings Faces Legal Challenges—What Investors Should Know

Updated Category News Views 365

Understanding the Recent Class Action Lawsuit Against Celsius Holdings Recently, Celsius Holdings, Inc. (NASDAQ: CELH) has found itself at the center of a significant legal challenge. This class action lawsuit, filed by a prominent law firm, seeks to address serious allegations involving the company's financial disclosures and dealings with PepsiCo, Inc. The Accusations...

Continue Reading
Five Star Bancorp Announces Next Cash Dividend for Shareholders

Updated Category News Views 138

Five Star Bancorp's Dividend Announcement Five Star Bancorp (Nasdaq: FSBC) is pleased to share exciting news regarding its latest shareholder return strategy. The company has declared a cash dividend amounting to $0.20 per share on its voting common stock. This marks a continuing commitment to delivering value to its shareholders and is a pivotal part of the firm’s...

Continue Reading
Enovix Shares Decline as Q3 Report Shifts Market Sentiment

Updated Category News Views 151

Enovix Experiences Stock Decline Post Q3 Report Enovix Corporation (NASDAQ: ENVX) is facing a significant drop in its stock price as investors react to its recent third-quarter financial results. The company reported quarterly losses and provided guidance for the upcoming quarter that did not meet market expectations, leading to a decline in share value. Details of the...

Continue Reading
Borregaard ASA Launches Strategic Share Repurchase Program

Updated Category News Views 129

Borregaard ASA Announces Share Repurchase Initiative Borregaard ASA, known by the ticker OSE: BRG, is set to execute a strategic share repurchase program aiming to enhance shareholder value. This initiative involves the buyback of up to 200,000 shares of the company’s outstanding common stock. Purpose of the Share Repurchase Program The primary goal of this repurchase...

Continue Reading
Forian Expands Influence with Acquisition of Kyber Data Science

Updated Category News Views 103

Forian's Strategic Move to Acquire Kyber Data Science Forian Inc. (Nasdaq: FORA), a prominent data science company, is making headlines with its recent acquisition of Kyber Data Science LLC. This move is set to enhance Forian's capabilities in the healthcare analytics arena while also enabling the company to expand into the financial services sector. Kyber Data Science: A...

Continue Reading